Wall Street analysts predict that argenx SE – (NASDAQ:ARGX) will announce ($2.58) earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for argenx’s earnings, with estimates ranging from ($2.82) to ($1.98). The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that argenx will report full year earnings of ($10.08) per share for the current financial year, with EPS estimates ranging from ($11.07) to ($8.57). For the next financial year, analysts expect that the business will report earnings of ($11.53) per share, with EPS estimates ranging from ($15.15) to ($7.88). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow argenx.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.72) by ($0.15). The firm had revenue of $21.15 million during the quarter, compared to analyst estimates of $18.08 million.

ARGX has been the topic of several recent research reports. JMP Securities upped their price objective on argenx from $170.00 to $237.00 and gave the stock an “outperform” rating in a report on Tuesday, May 26th. Zacks Investment Research upgraded argenx from a “hold” rating to a “buy” rating and set a $239.00 price target on the stock in a report on Thursday, May 28th. Robert W. Baird increased their price target on argenx from $170.00 to $235.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Nomura Securities restated a “buy” rating and set a $255.00 price target on shares of argenx in a report on Wednesday, March 4th. Finally, Piper Sandler increased their price target on argenx from $198.00 to $258.00 in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $221.56.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Artisan Partners Limited Partnership grew its position in shares of argenx by 2.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,318,353 shares of the company’s stock worth $211,622,000 after buying an additional 36,439 shares in the last quarter. Wellington Management Group LLP grew its position in shares of argenx by 117.8% during the 1st quarter. Wellington Management Group LLP now owns 688,542 shares of the company’s stock worth $90,701,000 after buying an additional 372,436 shares in the last quarter. Franklin Resources Inc. grew its position in shares of argenx by 20.1% during the 4th quarter. Franklin Resources Inc. now owns 623,968 shares of the company’s stock worth $100,160,000 after buying an additional 104,441 shares in the last quarter. Capital World Investors grew its position in shares of argenx by 29.0% during the 4th quarter. Capital World Investors now owns 576,721 shares of the company’s stock worth $92,575,000 after buying an additional 129,588 shares in the last quarter. Finally, Jennison Associates LLC grew its position in shares of argenx by 47.9% during the 1st quarter. Jennison Associates LLC now owns 406,718 shares of the company’s stock worth $53,577,000 after buying an additional 131,737 shares in the last quarter. 54.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of ARGX traded down $1.22 during mid-day trading on Monday, hitting $223.29. 148,102 shares of the stock were exchanged, compared to its average volume of 172,661. The company has a market cap of $10.51 billion, a PE ratio of -47.21 and a beta of 1.22. argenx has a 52-week low of $103.75 and a 52-week high of $242.37. The firm has a 50-day moving average of $200.42 and a two-hundred day moving average of $160.94.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Further Reading: Circuit Breakers

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.